Epacadostat
Epacadostat is an investigational drug that acts as an inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). It is being studied for its potential use in cancer immunotherapy.
Mechanism of Action[edit | edit source]
Epacadostat works by inhibiting the activity of IDO1, an enzyme that is involved in the metabolism of tryptophan into kynurenine. IDO1 is often overexpressed in various types of tumors, leading to an immunosuppressive environment that allows cancer cells to evade the immune system. By blocking IDO1, epacadostat aims to restore the immune system's ability to recognize and attack cancer cells.
Clinical Development[edit | edit source]
Epacadostat has been evaluated in several clinical trials for its efficacy and safety in treating different types of cancer. It has been studied both as a monotherapy and in combination with other immunotherapeutic agents, such as checkpoint inhibitors like pembrolizumab and nivolumab.
Key Clinical Trials[edit | edit source]
- ECHO-301/KEYNOTE-252: This was a Phase 3 clinical trial that evaluated the combination of epacadostat and pembrolizumab in patients with advanced melanoma. The trial did not meet its primary endpoint of progression-free survival.
- ECHO-202/KEYNOTE-037: This Phase 1/2 trial investigated the combination of epacadostat and pembrolizumab in patients with various advanced solid tumors, including non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma.
Side Effects[edit | edit source]
The most common side effects observed in clinical trials of epacadostat include fatigue, nausea, rash, and diarrhea. Serious adverse events have also been reported, including immune-related adverse events.
Future Directions[edit | edit source]
Despite the setback in the ECHO-301/KEYNOTE-252 trial, research continues to explore the potential of IDO1 inhibitors like epacadostat in combination with other therapeutic agents. Ongoing studies are investigating different dosing regimens, combinations with other immunotherapies, and the identification of biomarkers that may predict response to treatment.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
